Sentry Investment Management LLC lifted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,068 shares of the biopharmaceutical company’s stock after buying an additional 1,326 shares during the quarter. Sentry Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $7,359,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC grew its position in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the period. Atlantic Trust LLC acquired a new position in Bristol-Myers Squibb in the second quarter valued at about $111,000. American National Bank lifted its stake in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares during the period. Blue Chip Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the period. Finally, BDO Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the second quarter worth about $123,000. 69.82% of the stock is owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.13 on Friday. The firm has a market cap of $103,881.36, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 2.41 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the prior year, the firm posted $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

BMY has been the subject of several research reports. Credit Suisse Group reissued a “hold” rating and set a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Cowen restated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group boosted their price objective on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Leerink Swann increased their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $64.93.

COPYRIGHT VIOLATION WARNING: “Sentry Investment Management LLC Has $7.36 Million Stake in Bristol-Myers Squibb Company (BMY)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/15/sentry-investment-management-llc-has-7-36-million-stake-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.